(Bloomberg) -- Goldman Sachs Group Inc.’s alternative investment arm has agreed to buy a majority stake in Dutch generic drugmaker Synthon from BC Partners. 

BC Partners will keep a minority holding in Synthon to support future growth, according to a statement Monday, which confirmed an earlier Bloomberg News report. It didn’t provide financial details. 

Bloomberg News reported earlier that the Goldman unit had beat out other suitors for Synthon and could value the drugmaker at about €2 billion ($2.1 billion).

Founded in 1991, Synthon International develops and manufactures generic drugs for therapeutic areas including oncology, central nervous system and cardiovascular, its website shows. The Netherlands-based company has offices in Argentina, Chile, the Czech Republic, South Korea, Mexico and Spain.

BC Partners acquired a majority stake in Synthon for $750 million in 2019 from the drugmaker’s founder, who remained invested as a minority shareholder. Since then, BC Partners has more than doubled Synthon’s operating profit, it said. 

With the latest transaction, the private equity firm has monetized €13 billion of assets over the past 18 months, according to Monday’s statement. BC Partners recently sold its controlling stake in Canadian security services firm GardaWorld. It has also floated publisher Springer Nature in Germany, sold Italian frozen pastry and bakery products maker Forno d’Asolo and offloaded a stake in IMA Industria Macchine Automatiche SpA to US merchant bank BDT & MSD Partners. 

The Synthon sale is expected to close in the second quarter of 2025. BC Partners was advised by Rothschild & Co., Barclays and PwC on the deal. 

©2024 Bloomberg L.P.